Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study

Area of Science:

• Biochemistry
• Pharmacology
• Vascular Biology

Background:

• Recombinant tissue plasminogen activator (rt-PA) is the primary FDA-approved therapy for acute ischemic stroke.
• Intra-cerebral hemorrhage is a significant complication of rt-PA therapy.
• GP IIb-IIIa inhibitors are being investigated as adjuncts to rt-PA, but combined therapy data is limited.

Purpose of the Study:

• To measure clot lysis efficacy of rt-PA and eptifibatide in an in vitro human clot model.
• To determine the drug concentrations that maximize clot lysis.
• To compare in vitro drug concentrations with those expected in clinical trials.

Main Methods:

• Human whole blood clots were generated from 28 volunteers.
• Clots were exposed to varying concentrations of rt-PA and eptifibatide in fresh-frozen plasma for 30 minutes at 37°C.
• Mean fractional clot loss (FCL) was measured using microscopic imaging to assess lytic efficacy.

Main Results:

• Control clots showed 14% FCL.
• Clots exposed to both drugs exhibited 58% FCL, except at high concentrations of rt-PA (3.15 μg/ml) and eptifibatide (1.26 or 2.31 μg/ml), where FCL decreased to 43% and 35%, respectively.
• Maximal clot lysis was observed at moderate concentrations of both rt-PA and eptifibatide.

Conclusions:

• Optimal clot lysis is achieved with moderate concentrations of rt-PA and eptifibatide.
• These concentrations may align with those used in certain clinical rt-PA and eptifibatide treatments.
• Further research into combined therapy protocols is warranted.